SG11202000086PA - Mpo inhibitors for use in medicine - Google Patents
Mpo inhibitors for use in medicineInfo
- Publication number
- SG11202000086PA SG11202000086PA SG11202000086PA SG11202000086PA SG11202000086PA SG 11202000086P A SG11202000086P A SG 11202000086PA SG 11202000086P A SG11202000086P A SG 11202000086PA SG 11202000086P A SG11202000086P A SG 11202000086PA SG 11202000086P A SG11202000086P A SG 11202000086PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cambridge
- pct
- oaa
- july
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762533448P | 2017-07-17 | 2017-07-17 | |
| PCT/EP2018/068992 WO2019016074A1 (en) | 2017-07-17 | 2018-07-12 | DFO INHIBITORS FOR USE IN MEDICINE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000086PA true SG11202000086PA (en) | 2020-02-27 |
Family
ID=62904484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000086PA SG11202000086PA (en) | 2017-07-17 | 2018-07-12 | Mpo inhibitors for use in medicine |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11246870B2 (ru) |
| EP (1) | EP3654983B1 (ru) |
| JP (1) | JP7220193B2 (ru) |
| KR (1) | KR20200029513A (ru) |
| CN (1) | CN110891572B (ru) |
| AU (1) | AU2018304508B2 (ru) |
| BR (1) | BR112019026270A2 (ru) |
| CA (1) | CA3068910A1 (ru) |
| EA (1) | EA202090266A1 (ru) |
| ES (1) | ES2963315T3 (ru) |
| IL (1) | IL272043B (ru) |
| MA (1) | MA49618A (ru) |
| SG (1) | SG11202000086PA (ru) |
| WO (1) | WO2019016074A1 (ru) |
| ZA (1) | ZA202000904B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200029513A (ko) | 2017-07-17 | 2020-03-18 | 아스트라제네카 아베 | 의약에서의 사용을 위한 mpo 억제제 |
| AU2020363903A1 (en) * | 2019-10-10 | 2022-03-24 | Biohaven Therapeutics Ltd. | Prodrugs of myeloperoxidase inhibitors |
| CN115403584B (zh) * | 2021-05-26 | 2024-04-02 | 长春金赛药业有限责任公司 | 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2362101A (en) * | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
| SE0201193D0 (sv) * | 2002-04-19 | 2002-04-19 | Astrazeneca Ab | Novel use |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| EA200800260A1 (ru) | 2005-07-05 | 2008-06-30 | ЭДИЛЕЙД ФЭТИЛИТИ СЭНТЭ ПиТиУай ЭлТиДи | Способы, композиция и комбинированный продукт для улучшения репродуктивного здоровья у особи мужского пола или улучшения исхода беременности у особи женского пола, сперма (варианты), способ ее получения и животный организм, не принадлежащий к человеческому роду, появившийся в результате оплодотворения указанной спермой |
| AR066936A1 (es) | 2007-06-13 | 2009-09-23 | Astrazeneca Ab | 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas. |
| US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
| JP5757604B2 (ja) * | 2010-02-05 | 2015-07-29 | ヒガシマル醤油株式会社 | ミエロペルオキシダーゼ阻害剤 |
| US9616063B2 (en) | 2014-12-01 | 2017-04-11 | Astrazeneca Ab | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase |
| US11241406B2 (en) | 2015-08-28 | 2022-02-08 | Nature's Sunshine Products, Inc. | Compositions and methods for acutley raising nitric oxide levels |
| KR20200029513A (ko) | 2017-07-17 | 2020-03-18 | 아스트라제네카 아베 | 의약에서의 사용을 위한 mpo 억제제 |
-
2018
- 2018-07-12 KR KR1020207003720A patent/KR20200029513A/ko not_active Application Discontinuation
- 2018-07-12 BR BR112019026270-9A patent/BR112019026270A2/pt unknown
- 2018-07-12 US US16/631,548 patent/US11246870B2/en active Active
- 2018-07-12 SG SG11202000086PA patent/SG11202000086PA/en unknown
- 2018-07-12 CA CA3068910A patent/CA3068910A1/en active Pending
- 2018-07-12 ES ES18740208T patent/ES2963315T3/es active Active
- 2018-07-12 JP JP2020500882A patent/JP7220193B2/ja active Active
- 2018-07-12 CN CN201880046928.XA patent/CN110891572B/zh active Active
- 2018-07-12 MA MA049618A patent/MA49618A/fr unknown
- 2018-07-12 WO PCT/EP2018/068992 patent/WO2019016074A1/en unknown
- 2018-07-12 AU AU2018304508A patent/AU2018304508B2/en active Active
- 2018-07-12 EP EP18740208.6A patent/EP3654983B1/en active Active
- 2018-07-12 EA EA202090266A patent/EA202090266A1/ru unknown
- 2018-07-12 IL IL272043A patent/IL272043B/en unknown
-
2020
- 2020-02-12 ZA ZA2020/00904A patent/ZA202000904B/en unknown
-
2021
- 2021-12-02 US US17/457,269 patent/US11738027B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018304508B2 (en) | 2021-06-10 |
| US20220160715A1 (en) | 2022-05-26 |
| AU2018304508A1 (en) | 2020-02-27 |
| NZ761505A (en) | 2023-09-29 |
| BR112019026270A2 (pt) | 2020-06-30 |
| EA202090266A1 (ru) | 2020-06-05 |
| US20200206226A1 (en) | 2020-07-02 |
| EP3654983B1 (en) | 2023-08-30 |
| JP2020527137A (ja) | 2020-09-03 |
| EP3654983A1 (en) | 2020-05-27 |
| ES2963315T3 (es) | 2024-03-26 |
| CN110891572B (zh) | 2023-08-15 |
| IL272043B (en) | 2022-09-01 |
| WO2019016074A1 (en) | 2019-01-24 |
| MA49618A (fr) | 2020-05-27 |
| ZA202000904B (en) | 2023-04-26 |
| CA3068910A1 (en) | 2019-01-24 |
| US11246870B2 (en) | 2022-02-15 |
| IL272043A (en) | 2020-03-31 |
| KR20200029513A (ko) | 2020-03-18 |
| US11738027B2 (en) | 2023-08-29 |
| CN110891572A (zh) | 2020-03-17 |
| JP7220193B2 (ja) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201909041SA (en) | Anti-pd-l1 antibody and use thereof | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer |